Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients
To evaluate the clinical and serologic profile, the rate of progression to well defined CTD and the possible predictors of disease evolution in patients affected by UCTD with antibodies anti-RoISSA. 148 patients diagnosed as UCTD were retrospectively evaluated. Antibodies to SSA/Ro were determined b...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2001-07, Vol.19 (4), p.403-409 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 409 |
|---|---|
| container_issue | 4 |
| container_start_page | 403 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 19 |
| creator | CAVAZZANA, I FRANCESCHINI, F BELFIORE, N QUINZANINI, M CAPORALI, R CALZAVARA-PINTON, P BETTONI, L BRUCATO, A CATTANEO, R MONTECUCCO, C |
| description | To evaluate the clinical and serologic profile, the rate of progression to well defined CTD and the possible predictors of disease evolution in patients affected by UCTD with antibodies anti-RoISSA.
148 patients diagnosed as UCTD were retrospectively evaluated. Antibodies to SSA/Ro were determined by counter-immunoelectrophoresis and ELISA.
Thirty-six patients (24.3%) developed a well-defined CTD after a mean follow-up of 4.5 years. Most patients developed primary Sjögren's syndrome (SS) (50%) or systemic lupus erythematosus (SLE) (30.5%). Leukopenia and xerophthalmia developed more frequently in the group of patients evolving to defined CTDs (p < 0.0032 and p < 0.0063). Leukopenia independently predicted the evolution in CTD by multivariate regression analysis (p < 0.019). Anti-dsDNA predicted the evolution in SLE (p < 0.0207), while the presence of additional anti-ENA specificity to anti-Ro/SSA was not associated with the outcome.
24.3% of patients with UCTD and antibodies to Ro/SSA can progress in a relatively short period of time to well-defined CTDs. The development of primary SS could be predicted by xerophthalmia and SLE by the appearance of anti-dsDNA antibodies. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71072871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71072871</sourcerecordid><originalsourceid>FETCH-LOGICAL-p237t-6ad0de7335ae031382c64f62401e70cce77640ed1b1073647080330560dd7d5d3</originalsourceid><addsrcrecordid>eNpF0EtLAzEQAOAgiq3VvyC56G0x2Wwe9SbFFxQEa6G3JU0mGNkm6yZr8d8bsCIMzGG-mWHmCE0pn7OKzNXmGE0Jm9eV4mIzQWcpfRBSCy7kKZpQ2sxL8Cka18F652CAkL3OYLGJIYDJ_gtw9imNgK1PoBPgvc_vWBe3jdZDwjni13izWt3d4kXngze6ww50HodS1MFiF7su7quxx9Fh2ijc6-zLonSOTpzuElwc8gytH-7fFk_V8uXxeXG3rPqayVwJbYkFyRjXQBhlqjaicaJuCAVJjAEpRUPA0i0lkolGEkUYI1wQa6Xlls3Q9e_cfoifI6Tc7nwy0HU6QBxTK0tfrSQt8PIAx-0ObNsPfqeH7_bvUQVcHYBO5U436GB8-ncNUZIrwX4A0sxygQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71072871</pqid></control><display><type>article</type><title>Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>CAVAZZANA, I ; FRANCESCHINI, F ; BELFIORE, N ; QUINZANINI, M ; CAPORALI, R ; CALZAVARA-PINTON, P ; BETTONI, L ; BRUCATO, A ; CATTANEO, R ; MONTECUCCO, C</creator><creatorcontrib>CAVAZZANA, I ; FRANCESCHINI, F ; BELFIORE, N ; QUINZANINI, M ; CAPORALI, R ; CALZAVARA-PINTON, P ; BETTONI, L ; BRUCATO, A ; CATTANEO, R ; MONTECUCCO, C</creatorcontrib><description>To evaluate the clinical and serologic profile, the rate of progression to well defined CTD and the possible predictors of disease evolution in patients affected by UCTD with antibodies anti-RoISSA.
148 patients diagnosed as UCTD were retrospectively evaluated. Antibodies to SSA/Ro were determined by counter-immunoelectrophoresis and ELISA.
Thirty-six patients (24.3%) developed a well-defined CTD after a mean follow-up of 4.5 years. Most patients developed primary Sjögren's syndrome (SS) (50%) or systemic lupus erythematosus (SLE) (30.5%). Leukopenia and xerophthalmia developed more frequently in the group of patients evolving to defined CTDs (p < 0.0032 and p < 0.0063). Leukopenia independently predicted the evolution in CTD by multivariate regression analysis (p < 0.019). Anti-dsDNA predicted the evolution in SLE (p < 0.0207), while the presence of additional anti-ENA specificity to anti-Ro/SSA was not associated with the outcome.
24.3% of patients with UCTD and antibodies to Ro/SSA can progress in a relatively short period of time to well-defined CTDs. The development of primary SS could be predicted by xerophthalmia and SLE by the appearance of anti-dsDNA antibodies.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 11491495</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Antinuclear - blood ; Arthralgia - etiology ; Arthralgia - pathology ; Autoantigens - blood ; Biological and medical sciences ; Child ; Disease Progression ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Immunoelectrophoresis ; Interleukin-8 - analogs & derivatives ; Interleukin-8 - immunology ; Leukopenia - etiology ; Leukopenia - pathology ; Lupus Erythematosus, Systemic - etiology ; Lupus Erythematosus, Systemic - pathology ; Male ; Medical sciences ; Middle Aged ; Mixed Connective Tissue Disease - complications ; Mixed Connective Tissue Disease - diagnosis ; Mixed Connective Tissue Disease - immunology ; Mixed Connective Tissue Disease - physiopathology ; Retrospective Studies ; Ribonucleoproteins - blood ; RNA, Small Cytoplasmic ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sjogren's Syndrome - etiology ; Sjogren's Syndrome - pathology ; Xerophthalmia - etiology ; Xerophthalmia - pathology</subject><ispartof>Clinical and experimental rheumatology, 2001-07, Vol.19 (4), p.403-409</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14087586$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11491495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CAVAZZANA, I</creatorcontrib><creatorcontrib>FRANCESCHINI, F</creatorcontrib><creatorcontrib>BELFIORE, N</creatorcontrib><creatorcontrib>QUINZANINI, M</creatorcontrib><creatorcontrib>CAPORALI, R</creatorcontrib><creatorcontrib>CALZAVARA-PINTON, P</creatorcontrib><creatorcontrib>BETTONI, L</creatorcontrib><creatorcontrib>BRUCATO, A</creatorcontrib><creatorcontrib>CATTANEO, R</creatorcontrib><creatorcontrib>MONTECUCCO, C</creatorcontrib><title>Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To evaluate the clinical and serologic profile, the rate of progression to well defined CTD and the possible predictors of disease evolution in patients affected by UCTD with antibodies anti-RoISSA.
148 patients diagnosed as UCTD were retrospectively evaluated. Antibodies to SSA/Ro were determined by counter-immunoelectrophoresis and ELISA.
Thirty-six patients (24.3%) developed a well-defined CTD after a mean follow-up of 4.5 years. Most patients developed primary Sjögren's syndrome (SS) (50%) or systemic lupus erythematosus (SLE) (30.5%). Leukopenia and xerophthalmia developed more frequently in the group of patients evolving to defined CTDs (p < 0.0032 and p < 0.0063). Leukopenia independently predicted the evolution in CTD by multivariate regression analysis (p < 0.019). Anti-dsDNA predicted the evolution in SLE (p < 0.0207), while the presence of additional anti-ENA specificity to anti-Ro/SSA was not associated with the outcome.
24.3% of patients with UCTD and antibodies to Ro/SSA can progress in a relatively short period of time to well-defined CTDs. The development of primary SS could be predicted by xerophthalmia and SLE by the appearance of anti-dsDNA antibodies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Arthralgia - etiology</subject><subject>Arthralgia - pathology</subject><subject>Autoantigens - blood</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Disease Progression</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoelectrophoresis</subject><subject>Interleukin-8 - analogs & derivatives</subject><subject>Interleukin-8 - immunology</subject><subject>Leukopenia - etiology</subject><subject>Leukopenia - pathology</subject><subject>Lupus Erythematosus, Systemic - etiology</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mixed Connective Tissue Disease - complications</subject><subject>Mixed Connective Tissue Disease - diagnosis</subject><subject>Mixed Connective Tissue Disease - immunology</subject><subject>Mixed Connective Tissue Disease - physiopathology</subject><subject>Retrospective Studies</subject><subject>Ribonucleoproteins - blood</subject><subject>RNA, Small Cytoplasmic</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sjogren's Syndrome - etiology</subject><subject>Sjogren's Syndrome - pathology</subject><subject>Xerophthalmia - etiology</subject><subject>Xerophthalmia - pathology</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0EtLAzEQAOAgiq3VvyC56G0x2Wwe9SbFFxQEa6G3JU0mGNkm6yZr8d8bsCIMzGG-mWHmCE0pn7OKzNXmGE0Jm9eV4mIzQWcpfRBSCy7kKZpQ2sxL8Cka18F652CAkL3OYLGJIYDJ_gtw9imNgK1PoBPgvc_vWBe3jdZDwjni13izWt3d4kXngze6ww50HodS1MFiF7su7quxx9Fh2ijc6-zLonSOTpzuElwc8gytH-7fFk_V8uXxeXG3rPqayVwJbYkFyRjXQBhlqjaicaJuCAVJjAEpRUPA0i0lkolGEkUYI1wQa6Xlls3Q9e_cfoifI6Tc7nwy0HU6QBxTK0tfrSQt8PIAx-0ObNsPfqeH7_bvUQVcHYBO5U436GB8-ncNUZIrwX4A0sxygQ</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>CAVAZZANA, I</creator><creator>FRANCESCHINI, F</creator><creator>BELFIORE, N</creator><creator>QUINZANINI, M</creator><creator>CAPORALI, R</creator><creator>CALZAVARA-PINTON, P</creator><creator>BETTONI, L</creator><creator>BRUCATO, A</creator><creator>CATTANEO, R</creator><creator>MONTECUCCO, C</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients</title><author>CAVAZZANA, I ; FRANCESCHINI, F ; BELFIORE, N ; QUINZANINI, M ; CAPORALI, R ; CALZAVARA-PINTON, P ; BETTONI, L ; BRUCATO, A ; CATTANEO, R ; MONTECUCCO, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p237t-6ad0de7335ae031382c64f62401e70cce77640ed1b1073647080330560dd7d5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Arthralgia - etiology</topic><topic>Arthralgia - pathology</topic><topic>Autoantigens - blood</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Disease Progression</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoelectrophoresis</topic><topic>Interleukin-8 - analogs & derivatives</topic><topic>Interleukin-8 - immunology</topic><topic>Leukopenia - etiology</topic><topic>Leukopenia - pathology</topic><topic>Lupus Erythematosus, Systemic - etiology</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mixed Connective Tissue Disease - complications</topic><topic>Mixed Connective Tissue Disease - diagnosis</topic><topic>Mixed Connective Tissue Disease - immunology</topic><topic>Mixed Connective Tissue Disease - physiopathology</topic><topic>Retrospective Studies</topic><topic>Ribonucleoproteins - blood</topic><topic>RNA, Small Cytoplasmic</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sjogren's Syndrome - etiology</topic><topic>Sjogren's Syndrome - pathology</topic><topic>Xerophthalmia - etiology</topic><topic>Xerophthalmia - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CAVAZZANA, I</creatorcontrib><creatorcontrib>FRANCESCHINI, F</creatorcontrib><creatorcontrib>BELFIORE, N</creatorcontrib><creatorcontrib>QUINZANINI, M</creatorcontrib><creatorcontrib>CAPORALI, R</creatorcontrib><creatorcontrib>CALZAVARA-PINTON, P</creatorcontrib><creatorcontrib>BETTONI, L</creatorcontrib><creatorcontrib>BRUCATO, A</creatorcontrib><creatorcontrib>CATTANEO, R</creatorcontrib><creatorcontrib>MONTECUCCO, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CAVAZZANA, I</au><au>FRANCESCHINI, F</au><au>BELFIORE, N</au><au>QUINZANINI, M</au><au>CAPORALI, R</au><au>CALZAVARA-PINTON, P</au><au>BETTONI, L</au><au>BRUCATO, A</au><au>CATTANEO, R</au><au>MONTECUCCO, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>19</volume><issue>4</issue><spage>403</spage><epage>409</epage><pages>403-409</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>To evaluate the clinical and serologic profile, the rate of progression to well defined CTD and the possible predictors of disease evolution in patients affected by UCTD with antibodies anti-RoISSA.
148 patients diagnosed as UCTD were retrospectively evaluated. Antibodies to SSA/Ro were determined by counter-immunoelectrophoresis and ELISA.
Thirty-six patients (24.3%) developed a well-defined CTD after a mean follow-up of 4.5 years. Most patients developed primary Sjögren's syndrome (SS) (50%) or systemic lupus erythematosus (SLE) (30.5%). Leukopenia and xerophthalmia developed more frequently in the group of patients evolving to defined CTDs (p < 0.0032 and p < 0.0063). Leukopenia independently predicted the evolution in CTD by multivariate regression analysis (p < 0.019). Anti-dsDNA predicted the evolution in SLE (p < 0.0207), while the presence of additional anti-ENA specificity to anti-Ro/SSA was not associated with the outcome.
24.3% of patients with UCTD and antibodies to Ro/SSA can progress in a relatively short period of time to well-defined CTDs. The development of primary SS could be predicted by xerophthalmia and SLE by the appearance of anti-dsDNA antibodies.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>11491495</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2001-07, Vol.19 (4), p.403-409 |
| issn | 0392-856X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71072871 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Antinuclear - blood Arthralgia - etiology Arthralgia - pathology Autoantigens - blood Biological and medical sciences Child Disease Progression Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Humans Immunoelectrophoresis Interleukin-8 - analogs & derivatives Interleukin-8 - immunology Leukopenia - etiology Leukopenia - pathology Lupus Erythematosus, Systemic - etiology Lupus Erythematosus, Systemic - pathology Male Medical sciences Middle Aged Mixed Connective Tissue Disease - complications Mixed Connective Tissue Disease - diagnosis Mixed Connective Tissue Disease - immunology Mixed Connective Tissue Disease - physiopathology Retrospective Studies Ribonucleoproteins - blood RNA, Small Cytoplasmic Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Sjogren's Syndrome - etiology Sjogren's Syndrome - pathology Xerophthalmia - etiology Xerophthalmia - pathology |
| title | Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A45%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Undifferentiated%20connective%20tissue%20disease%20with%20antibodies%20to%20Ro/SSA:%20Clinical%20features%20and%20follow-up%20of%20148%20patients&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=CAVAZZANA,%20I&rft.date=2001-07-01&rft.volume=19&rft.issue=4&rft.spage=403&rft.epage=409&rft.pages=403-409&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71072871%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71072871&rft_id=info:pmid/11491495&rfr_iscdi=true |